Efficacy and safety of vildagliptin/pioglitazone combination therapy in Korean patients with diabetes

doi:10.4239/wjd.v1.i5.153

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 1, Issue 5

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3982)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-3) series, Tables (1-2) series.

Item

Count

PDF

374

HTML

2885

Figures (1-3)

397

Tables (1-2)

326

Sum=3982

Nov 15, 2010 (publication date) through Dec 27, 2024

Times Cited of This Article

Times Cited (5)

Journal Information of This Article

Publication Name

World Journal of Diabetes

ISSN

1948-9358

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Articles

World J Diabetes. Nov 15, 2010; 1(5): 153-160
Published online Nov 15, 2010. doi: 10.4239/wjd.v1.i5.153

Open in New Tab Full Size Figure Download Figure

Figure 1 Mean (± standard error) hemoglobin A_1c during 24-wk treatment with vildagliptin/pioglitazone combination (100/30 mg q. d. circles; 50/15 mg q.d. triangles), vildagliptin 100 mg q.d. (squares), or pioglitazone 30 mg q.d. (diamonds) in a Korean population. HbA_1c: hemoglobin A_1c.

Open in New Tab Full Size Figure Download Figure

Figure 2 Mean (± standard error) fasting plasma glucose during 24-wk treatment with vildagliptin/pioglitazone combination (100/30 mg q. d. circles; 50/15 mg q.d. triangles), vildagliptin 100 mg q.d. (squares), or pioglitazone 30 mg q.d. (diamonds) in a Korean population. FPG: fasting plasma glucose.

Open in New Tab Full Size Figure Download Figure

Figure 3 Mean (± standard error) change in the indicated prandial variables at endpoint, following treatment with vildagliptin/pioglitazone combination (100/30 mg q. d. or 50/15 mg q.d.), vildagliptin 100 mg q.d., or pioglitazone 30 mg q.d., in patients that volunteered for the meal test. ^aSignificant difference compared with pioglitazone 30 mg q.d. monotherapy.

Citation: Kim SW, Baik SH, Yoon KH, Lee HW, Filozof C. Efficacy and safety of vildagliptin/pioglitazone combination therapy in Korean patients with diabetes. World J Diabetes 2010; 1(5): 153-160
URL: https://www.wjgnet.com/1948-9358/full/v1/i5/153.htm
DOI: https://dx.doi.org/10.4239/wjd.v1.i5.153